 "Vaccine will be available only after trials are successful: Serum Institute")
Amidst reports claiming Serum Institute of India would be ready with Covishield vaccine in 73 days, the Pune-based company on Sunday clarified that these claims were misleading.
“The government has granted us permission to only manufacture the vaccine and stockpile it for future use,” Serum Institute said on Sunday. The drugmaker said the vaccine would be commercialised once the trials are proven successful and all the requisite regulatory approvals are in place. It said the claims surrounding Covishield's availability in the media were “conjectural”.
ALSO READ: India to have coronavirus vaccine by 2020 end, says Harsh Vardhan
Covishield is the vaccine candidate from Oxford-AstraZeneca that is under development. Serum Institute began phase-II trials in India last week.
The phase-III trials for the Oxford-AstraZeneca vaccine are underway. “Only once the vaccine is proven immunogenic and efficacious, we will confirm its availability, officially,” the firm said. Union Health Minister Harsh Vardhan had said on Saturday that “one of India’s Covid-19 vaccine candidates is in the third phase of clinical trials” and that a vaccine will be developed “by the end of this year”.
According to experts, phase-III trials typically take 3-6 months, even if they are expedited.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%